ICDD 2026
April 22–23, 2026
Budapest, Hungary
Medicilon Signs Five-Year Strategic Cooperation Agreement with BioPartners X to Jointly Promote Innovative Drug R&D
On March 31, 2026, Medicilon officially signed a long-term strategic cooperation framework agreement with BioPartners X. Mr. Gong Huimin, Chairman and CEO of BioPartners X, Dr. Liu Tong, Chief Scientist, Mr. Luo Wusong and Mr. Xu Changlu, Vice Presidents of Strategic Investment, and Mr. Li Ao, Non-Clinical Director, together with Dr. Chen Chunlin, Founder and […]
Medicilon and Protheragen Forge Strategic Partnership to Build a Collaborative “Project + Platform” Model
On April 6, Medicilon formally signed a strategic cooperation agreement with Protheragen and its affiliated companies. Leveraging a collaborative “Project + Platform” model, the two parties will integrate Protheragen’s strengths in innovative drug incubation and global project sourcing with Medicilon’s one-stop preclinical pharmaceutical R&D service platform, jointly building an efficient, compliant and internationalized drug R&D […]
AOC Development: Conjugation Site Selection, DAR Control & In Vitro Testing | Full Webinar
Oligonucleotide therapeutics hold great promise, but extrahepatic delivery remains a challenge. Antibody–oligonucleotide conjugates (AOCs) are emerging as a powerful solution – provided you can master conjugation chemistry, DAR control, analytical characterization, and functional assessment. https://www.youtube.com/watch?v=CNr9ZsU2qrk In this recorded webinar, our experts from Medicilon cover: How conjugation chemistry impacts AOC consistency and developability Why DAR control […]
BioTrinity 2026
April 14-15, 2026
Convene, 133 Houndsditch, London EC3A 7BX, United Kingdom
Medicilon and Hailu Biotech of Yangtze River Pharmaceutical Group Forge Strategic Cooperation to Accelerate New Drug R&D and Global Outreach
On March 30, Medicilon held a strategic cooperation signing ceremony with Suzhou Hailu Biotech, a wholly-owned subsidiary of Yangtze River Pharmaceutical Group. The collaboration will focus on deepening synergy in preclinical new drug R&D, project introduction, and global market expansion, with the goal of jointly building an efficient, open, and international R&D ecosystem spanning from source […]
Oligonucleotide Therapeutics: Conjugation Chemistry & In Vitro Activity Assessment
April 8, 2026
8:00-9:00 PM ET (5:00–6:00 PM PT)
BIO-Europe Spring 2026
March 23, 2026,
to March 25, 2026
Medicilion Congratulates MediLink Therapeutics on Licensing B7H3 ADC to Roche
Recently, MediLink Therapeutics entered into a new exclusive license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY), a global pharmaceutical giant, for YL201, an antibody-drug conjugate (ADC) targeting B7H3.This landmark deal, featuring an upfront payment and near-term milestone payments exceeding USD 570 million, not only serves as a strong recognition of the substantial clinical value and […]
Building a New-Drug Expressway Together, Medicilon 2025 Year-End Review
For Medicilon, 2025 was a year of steady execution and meaningful progress, strengthening our foundations, expanding our global footprint, and working closely with partners around the world to move innovative medicines forward. Throughout the year, we continued to integrate discovery, development, and regulatory readiness, connecting early scientific innovation with global clinical and regulatory pathways. Step […]
